Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1ФГБУ «Национальный медицинский исследовательский центр психиатрии и неврологии им. В.М.Бехтерева» Минздрава России. 192019, Россия, Санкт-Петербург, ул. Бехтерева, д. 3; 2ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России. 125993, Россия, Москва, ул. Баррикадная, д. 2/1; 3СПб ГБУЗ «Больница №1 им. П.П.Кащенко». 188357, Россия, Ленинградская обл., с. Никольское, ул. Меньковская, д. 10 sosin.dmitriy@gmail.com
Список исп. литературыСкрыть список 1. Iasevoli F, Avagliano C, Altavilla B et al. Evaluation of a few discrete clinical markers may predict categorization of actively symptomatic non-acute schizophrenia patients as treatment resistant or responders: A study by ROC curve analysis and multivariate analyses. Psychiatry Res 2018; 269: 481–93. DOI: 10.1016/j. psychres.2018.08.109 2. Lally J, MacCabe JH. Antipsychotic medication in schizophrenia: a review. Br Med Bull 2015; 114 (1): 169–79. DOI: 10.1093/ bmb/ldv017 3. Iasevoli F, Giordano S, Balletta R et al. Treatment resistant schizophrenia is associated with the worst community functioning among severely-ill highly-disabling psychiatric conditions and is the most relevant predictor of poorer achievements in functional milestones. Prog Neuropsychopharmacol Biol Psychiatry 2016; 65: 34–48. DOI: 10.1016/j.pnpbp.2015.08.010 4. Kennedy JL, Altar CA, Taylor DL et al. The social and economic burden of treatment-resistant schizophrenia: a systematic literature review. Int Clin Psychopharmacol 2014; 29 (2): 63–76. DOI: 10.1097/YIC.0b013e32836508e6 5. Мазо Г.Э., Горобец Л.Н. Замена антипсихотика как метод предотвращения формирования резистентности при шизофрении. Обозрение психиатрии и мед. психологии. 2017; 3: 74–80. / Mazo G.E., Gorobets L.N. Zamena antipsikhotika kak metod predotvrashcheniia formirovaniia rezistentnosti pri shizofrenii. Obozrenie psikhiatrii i med. psikhologii. 2017; 3: 74–80. [in Russian] 6. Янушко М.Г., Иванов М.В., Сорокина А.В. Когнитивные нарушения при эндогенных психозах: современные представления в свете дименсионального подхода. Соц. и клин. психиатрия. 2014; 24 (1): 90–5. / Ianushko M.G., Ivanov M.V., Sorokina A.V. Kognitivnye narusheniia pri endogennykh psikhozakh: sovremennye predstavleniia v svete dimensional'nogo podkhoda. Sots. i klin. psikhiatriia. 2014; 24 (1): 90–5. [in Russian] 7. Keefe RS, Fenton WS. How should DSM-V criteria for schizophrenia include cognitive impairment? Schizophr Bull 2007; 33 (4): 912–20. 8. Woodward N, Meltzer H. Neuropsychologyoftreatment-resistantschizophrenia In: Elkis H, Meltzer H, editors. Therapy-resistant schizophrenia. Basel (Switzerland): Karger, 2010; p. 33–51. 9. Anderson VM, McIlwain ME, Kydd RR, Russell BR. Does cognitive impairment in treatment-resistant and ultra-treatment-resistant schizophrenia differ from that in treatment responders? Psychiatry Res 2015; 230 (3): 811–8. DOI: 10.1016/j.psychres.2015.10.036 10. Albert N, Randers L, Allott K et al. Cognitive functioning following discontinuation of antipsychotic medication. A naturalistic sub-group analysis from the OPUS II trial. Psychol Med 2018: 1–10. DOI: 10.1017/S0033291718001836 11. Medalia A, Gold J, Merriam A. The effects of neuroleptics on neuropsychological test results of schizophrenia. Arch Clin Neuropsychol 1988; 3 (3): 249–71. 12. Clissold M, Crowe SF. Comparing the effect of the subcategories of atypical antipsychotic medications on cognition in schizophrenia using a meta-analytic approach. J Clin Exp Neuropsychol 2018: 1–17. DOI: 10.1080/13803395.2018.1488952 13. Kontis D, Theochari E, Kleisas S et al. Doubtful association of antipsychotic polypharmacy and high dosage with cognition in chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34 (7): 1333–41. DOI: 10.1016/j.pnpbp.2010.07.029 14. Blokland GAM, Mesholam-Gately RI, Toulopoulou T et al. Heritability of neuropsychological measures in schizophrenia and nonpsychiatric populations: a systematic review and meta-analysis. Schizophr Bull 2017; 43 (4): 788–800. DOI: 10.1093/schbul/sbw146 15. Янушко М.Г., Сосин Д.Н., Шаманина М.В., Иванов М.В. Генетические корреляты когнитивных нарушений при шизофрении (обзор литературы). Сиб. вестн. психиатрии и наркологии. 2018; 2 (99): 98–103. DOI: 10.26617/1810-3111-2018-2 (99)-98-103 / Ianushko M.G., Sosin D.N., Shamanina M.V., Ivanov M.V. Geneticheskie korreliaty kognitivnykh narushenii pri shizofrenii (obzor literatury). Sib. vestn. psikhiatrii i narkologii. 2018; 2 (99): 98–103. DOI: 10.26617/1810-3111-2018-2 (99)-98-103 [in Russian] 16. Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014; 511: 421–7. 17. Kroken RA, Loberg EM, Dronen T et al. A critical review of pro-cognitive drug targets in psychosis: convergence on myelination and inflammation. Front Psychiatry 2014; 5: 11. DOI: 10.3389/ fpsyt.2014.00011 18. Stahl SM, Morrissette DA, Citrome L et al. "Meta-guidelines" for the management of patients with schizophrenia. CNS Spectr 2013; 18 (3): 150–62. DOI: 10.1017/S109285291300014X 19. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13 (2): 261–76. 20. Busner J, Targum SD. The Clinical Global Impressions Scale. Psychiatry (Edgmont) 2007; 4 (7): 28–37. 21. Endicott J, Spitzer RL, Fleiss JL, Cohen J. The global assessment scale: A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 1976; 33: 766–71. 22. Keefe RS, Fox KH, Davis VG et al. The Brief Assessment of Cognition In Affective Disorders (BAC-A): Performance of patients with bipolar depression and healthy controls. J Affect Dis 2014; 166: 86–92. DOI: 10.1016/j.jad.2014.05.002 23. De Bartolomeis A, Balletta R, Giordano S et al. Differential cognitive performances between schizophrenic responders and non-responders to antipsychotics: correlation with course of the illness, psychopathology, attitude to the treatment and antipsychotics doses. Psychiatry Res 2013; 210 (2): 387–95. DOI: 10.1016/j. psychres.2013.06.042 24. Cheng CM, Chang WH, Chiu YC et al. Association of Polypharmacy With Mild Cognitive Impairment and Cognitive Ability: A Nationwide Survey in Taiwan. J Clin Psychiatry 2018; 79 (6); pii: 17m12043. DOI: 10.4088/JCP.17m12043